Gainers & Losers Of The Day: EYES, SGNL, NEOT, DMTX, MBRX...

(RTTNews) - The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of February 7, 2017.

1. Second Sight Medical Products Inc. (EYES)

Gained 78.06% to close Tuesday's (Feb.7th) trading at $2.76. In after-hours, the stock was down over 11%.

News: The company has set February 10, 2017 as the record date for its rights offering.

Non-transferable subscription rights to purchase units, composed of a share of Second Sight common stock and a five-year warrant to purchase an additional share of common stock, will be issued in the offering. Each right will entitle the holder to invest $0.47 toward the purchase of units, each such unit, composed of one share of common stock and a warrant to purchase common stock, at a subscription price that is the lesser of $2.00 or the closing price per share of the common stock on Nasdaq on March 6, 2017, the close of the subscription period.

Near- term catalyst: The first human implant of the Orion I Visual Cortical Prosthesis will be performed in the first half of this year.

Orion I is an investigational device for restoring some vision to individuals who are blind due to causes other than preventable or treatable conditions.

Anticipated event: Q4 and full-year 2016 financial results to be reported on March 1, 2017.

2. PharmAthene Inc. (PIP)

Gained 35.64% to close Tuesday's trading at $1.37.

News: No news

Recent event:

A special one-time cash dividend of $2.91 per share of common stock was payable on February 3, 2017 to holders of record as of January 24, 2017.

Last month, PharmAthene and privately-held immunotherapeutics company Altimmune Inc., signed an agreement to merge in an all-stock transaction. The combined company, which will operate as a public company under the name Altimmune, is expected to trade on the NYSE MKT under the ticker symbol ALT.

The merger is subject to the approval of PharmAthene and Altimmune shareholders.

3. MYOS RENS Technology Inc. (MYOS)

Gained 30.75% to close Tuesday's trading at $4.72.

News: No news

Recent events:

A registered direct offering, announced on February 3, 2017, wherein the company agreed to sell 500,000 shares of its common stock to an institutional investor at a per share price of $4.25, is expected to take place on or about February 8, 2017.

MYOS RENS is the developer of muscle-health ingredient Fortetropin, the first clinically-proven, all natural myostatin-reducing agent. Fortetropin is the active ingredient in Re Muscle Health, a line of non-GMO protein bars, shakes, pudding mixes and powders that was launched in March 2015.

4. Signal Genetics Inc. (SGNL)

Gained 26.07% to close Tuesday's trading at $13.30.

News: No news

Anticipated event:

Last October, Signal Genetics and privately-held Miragen Therapeutics Inc. agreed to merge to create a clinical-stage, NASDAQ-listed, biopharmaceutical company developing proprietary micro RNA-targeted therapeutics. The combined company will change its name to Miragen Therapeutics Inc., and ticker to MRGN.

A special meeting of Signal stockholders related to the proposed merger with Miragen is scheduled for February 10, 2017. The proposed merger is expected to close in the first quarter of 2017.

Signal implemented a 1-for-15 reverse stock split of its common stock on November 7, 2016.

5. Esperion Therapeutics Inc. (ESPR)

Gained 14.04% to close Tuesday's trading at $20.14.

News: No news

Esperion's shares have been on the rise ever since Amgen Inc. (AMGN) announced on February 3rd, 2017 that its cholesterol lowering approved drug Repatha met the primary and secondary key endpoints in a landmark cardiovascular outcomes study, dubbed FOURIER.

Esperion is also developing a cholesterol lowering drug, which goes by the name Bempedoic acid.

Bempedoic acid is an inhibitor of ATP Citrate Lyase, and is under phase III testing. A global cardiovascular outcomes trial for Bempedoic acid, known as CLEAR Outcomes CVOT, was initiated by the company as recently as last month.

The top line results from one of the phase III studies of Bempedoic acid are expected by Q2 2018.

6. Neothetics Inc. (NEOT)

Gained 11.76% to close Tuesday's trading at $1.90. The stock has gained more than 31% in the last 5 trading days.

News: No news

Near-term catalyst: A phase II proof of concept trial of LIPO-202 for the reduction of submental subcutaneous fat is underway. Top-line data from this trial are expected in late second quarter 2017.

7. Galectin Therapeutics Inc. (GALT)

Gained 10.43% to close Tuesday's trading at $1.27.

News: The company made a presentation at GTCBio 9th Immunotherapeutics & Immunomonitoring Conference on February 7, 2017.

The company revealed that its key drug candidate GR-MD-02 plus immunotherapy augments augments antitumor immunity as can be seen by reduced metastases, increased tumor regression and improved survival.

A phase Ib trial of Galectin's GR-MD-02 in combination with Merck's (MRK) Keytruda in patients with advanced refractory metastatic melanoma and a phase Ib study of GR-MD-02 in combination with Bristol-Myers Squibb's (BMY) Yervoy in patients with malignant melanoma are underway.

Near-term catalyst:

GR-MD-02 is also being explored in other indications like non-alcoholic steatohepatitis (NASH) with advanced fibrosis and severe skin disease, including moderate to severe plaque psoriasis and severe atopic dermatitis.

The company remains on track to present top line data from its phase II trial of GR-MD-02 in patients with NASH cirrhosis, dubbed NASH-CX, by early December 2017.

8. Argos Therapeutics Inc. (ARGS)

Gained 10.23% to close Tuesday's trading at $4.85.

News: No news

Near-term catalyst:

An independent Data Monitoring Committee to review ADAPT, the company's phase III trial comparing ROCAPULDENCEL-T in combination with Pfizer's kidney-cancer drug Sutent against Sutent alone for the treatment of newly diagnosed patients with advanced renal cell cancer is expected to occur this month.

9. Orexigen Therapeutics Inc. (OREX)

Gained 9.31% to close Tuesday's trading at $4.58.

News: No news

Anticipated event:

The company will be presenting at two upcoming investor conferences.

- BIO CEO & Investor Conference on February 14, 2017 - Leerink Partners Global Healthcare Conference on February 16, 2017.

LOSERS

1. Dimension Therapeutics (DMTX)

Lost 13.16% to close Tuesday's trading at $1.65. The stock has lost over 62% in the last 5 trading days.

News: No news

Recent event: On January 31, 2017, the company reported interim top-line results from an ongoing phase I/II trial of DTX101 for the treatment of adult patients with moderate/severe to severe hemophilia B announced.

Hemophilia B is a rare genetic bleeding disorder resulting from a deficiency in FIX. Although all patients treated with DTX101 improved from moderate/severe-to-severe to either moderate or mild range in terms of factor levels based on World Federation of Hemophilia, asymptomatic elevations of alanine aminotransferase (ALT) were observed in 5 of 6 patients. One of the patients experienced a grade 4 adverse event due to an elevated ALT. Elevated level of ALT is an indicator of liver damage.

2. Moleculin Biotech Inc. (MBRX)

Lost 10% to close Tuesday's trading at $1.80.

News: No news

Near-term catalyst: Report data from phase II trial evaluating Annamycin as a potential treatment for relapsed or refractory acute myeloid leukemia by the second half of 2017.